SETDB1 as a cancer target: challenges and perspectives in drug design-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

SETDB1 as a cancer target: challenges and perspectives in drug design

Published:2024 Issue:5 Volume:15 Page:1424-1451
ISSN:2632-8682
Container-title:RSC Medicinal Chemistry
language:en
Short-container-title:RSC Med. Chem.

Author:

Hassanie Haifa¹^ORCID,Penteado André Berndt¹^ORCID,de Almeida Larissa Costa²^ORCID,Calil Raisa Ludmila¹,da Silva Emery Flávio³^ORCID,Costa-Lotufo Leticia Veras²^ORCID,Trossini Gustavo Henrique Goulart¹^ORCID

Affiliation:

1. School of Pharmaceutical Sciences, University of São Paulo, Brazil

2. Institute of Biomedical Sciences, University of São Paulo, Brazil

3. School of Pharmaceutical Sciences of the Ribeirão Preto, University of São Paulo, Brazil

Abstract

The SETDB1 protein's structure and primary function are succinctly described in this review article. It also gives light on potential inhibitory mechanisms that, in the future, can be employed as a cancer target.

Funder

Fundação de Amparo à Pesquisa do Estado de São Paulo

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior

Conselho Nacional de Desenvolvimento Científico e Tecnológico

Publisher

Royal Society of Chemistry (RSC)

Link

http://pubs.rsc.org/en/content/articlepdf/2024/MD/D3MD00366C

Reference174 articles.

1. The global challenge of cancer

2. Cancer as a disease of old age: changing mutational and microenvironmental landscapes

3. Super-enhancers: a new frontier for epigenetic modifiers in cancer chemoresistance

4. Lysine methyltransferase inhibitors: where we are now

5. Targeting epigenetic regulatory machinery to overcome cancer therapy resistance

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP